SCHEMBL29629206

SCHEMBL29629206

CSc1nccc(-c2sc(NC(=O)Nc3ccc(CN4CCN(C(C)=O)CC4)c(C(F)(F)F)c3)nc2C)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 7/20 0.47
NTRK1 P04629 2/20 0.47
NTRK2 Q16620 2/20 0.47
TEK Q02763 1/20 0.47
RET P07949 4/20 0.47
PIK3CA P42336 1/20 0.46
CDK8 P49336 5/20 0.46
CDK2 P24941 3/20 0.46
CDK1 P06493 2/20 0.46
SRC P12931 6/20 0.45
KDR P35968 3/20 0.43
CDK9 P50750 3/20 0.43
AURKA O14965 2/20 0.43
WEE1 P30291 2/20 0.43
CDK7 P50613 2/20 0.43
AURKB Q96GD4 2/20 0.43
ALK Q9UM73 2/20 0.43
CHEK1 O14757 1/20 0.43
DAPK3 O43293 1/20 0.43
JAK2 O60674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22684885 1.00 ABL1 (0.47) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068668 0.93 CDK8 (0.54) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629216 0.93 CDK8 (0.54) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068658 0.91 CDK8 (0.49) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629204 0.91 CDK8 (0.49) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629194 0.90 ABL1 (0.46) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068641 0.90 ABL1 (0.46) ABL1NTRK1NTRK2TEKRET
SCHEMBL23068652 0.89 CDK9 (0.53) ABL1NTRK1NTRK2TEKRET
SCHEMBL22684880 0.89 ABL1 (0.47) ABL1NTRK1NTRK2TEKRET
SCHEMBL29629248 0.89 ABL1 (0.47) ABL1NTRK1NTRK2TEKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740484-B1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-09-11 EP disclosed
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-03-23 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 ABL1 268/4885NTRK1 2045/4885NTRK2 3568/4885
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 ABL1 268/4885NTRK1 2045/4885NTRK2 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.